UK prescribing rules for Mounjaro and Ozempic
UK prescribing rules for GLP-1 medications follow MHRA licensing and NICE guidance. Mounjaro (tirzepatide) licensed for type 2 diabetes and weight management for adults meeting specific BMI criteria with comorbidities. Ozempic (semaglutide) licensed only for type 2 diabetes - using for weight loss is off-label. Wegovy (also semaglutide at higher doses) licensed specifically for weight management in adults meeting NICE criteria. NHS prescribing limited to adults meeting strict criteria including BMI thresholds and supervised weight management programmes. Private prescribing through specialist clinics expanded access for adults able to afford costs. Online providers exist but require legitimate prescribing - avoid unregulated sources. UK prescribing rules continue evolving with new medications and guidance.
UK prescribing context
UK prescribing rules for GLP-1 medications have specific structure. Understanding the framework helps make informed decisions through legitimate channels.
MHRA licensing determines uses
MHRA (Medicines and Healthcare products Regulatory Agency) licenses specific medications for specific uses. Mounjaro licensed for diabetes and weight management. Ozempic licensed only for diabetes. Wegovy licensed for weight management. The licensing determines legitimate uses.
NICE guidance determines NHS access
NICE (National Institute for Health and Care Excellence) provides guidance on NHS prescribing. Specific criteria define which adults can access medications through NHS. The guidance balances cost-effectiveness with clinical benefit.
BMI and comorbidity criteria
Weight management prescribing typically requires BMI 35 plus with comorbidities (diabetes, hypertension, sleep apnoea) or BMI 30 plus with specific conditions. Adults below thresholds typically don't qualify for NHS prescribing. Match expectations to criteria.
Specialist weight management context
NHS prescribing typically through specialist weight management services rather than GP. Adults need referral and assessment. The specialist context provides comprehensive care. GP can initiate referral process.
Private prescribing expanded access
Private specialist clinics prescribe weight loss medications for broader population. Costs 150 to 300 pounds monthly typically. Adults not meeting NHS criteria may access through private prescribing if meeting clinic criteria. The private route adds cost but expanded access.
Practical approach
Adults wanting to access GLP-1 medications legitimately can approach through specific routes.
Start with GP consultation
GP can assess eligibility, discuss options, refer to specialist services or private clinics if appropriate. The GP involvement is starting point regardless of NHS or private route. Don't bypass medical professionals.
Request specialist referral if NHS eligible
Adults meeting NHS criteria can request referral to specialist weight management services. The specialist context provides comprehensive care. Wait times vary substantially. Match expectations to current NHS capacity.
Consider regulated private clinics
Adults not eligible for NHS or unwilling to wait can consider private specialist clinics. Choose CQC registered clinics with proper medical oversight. Avoid online providers with minimal medical involvement. The regulation matters.
Avoid unregulated online sources
Online providers selling medications without proper prescribing have significant safety risks including counterfeit products, inadequate medical assessment, no monitoring. Legitimate prescribing involves proper medical assessment. Don't compromise on safety.
Understand long-term costs
Private prescribing 150 to 300 pounds monthly. NHS prescribing free at point of access for eligible adults. Calculate total over months and years. The cost matters substantially for sustainable use.
Legitimate prescribing matters
GLP-1 medications require legitimate prescribing through qualified medical professionals.
- Avoid unregulated online sources. Counterfeit products and inadequate medical oversight create significant risks.
- NHS access limited but available for eligible adults. Specialist services provide comprehensive care.
- Private prescribing expanded access but adds cost. Choose regulated clinics with proper medical oversight.
- BMI and comorbidity criteria affect access. Adults below thresholds may need other approaches.
- Prescribing rules evolve. Current rules may change - check current guidance with prescribing professionals.
UK prescribing rules for GLP-1 medications follow MHRA licensing and NICE guidance. Mounjaro licensed for diabetes and weight management. Ozempic licensed only for diabetes. Wegovy licensed for weight management. NHS prescribing limited to adults meeting strict criteria. Private prescribing through specialist clinics expanded access. Online providers require legitimate prescribing - avoid unregulated sources. Start with GP consultation. Consider specialist referral if NHS eligible. Choose regulated private clinics if not. Avoid unregulated sources. Understand long-term costs. The legitimate prescribing routes ensure proper medical assessment, monitoring and authentic medications.
For more on weight loss medications our Weight Loss Hub brings every guide together.
Back to the Weight Loss Hub
This article sits inside our complete weight loss knowledge base covering calorie management, nutrition, exercise, behaviour change, GLP-1 medications, plateaus, maintenance and the practical guidance behind sustainable weight loss. Head back to the hub for the full index.
More on GLP-1 medications
Prescribing rules connect to related topics. what Mounjaro is covers Mounjaro. what Ozempic is covers Ozempic. And Mounjaro vs Ozempic covers comparison.


Share:
Mounjaro and Ozempic and Exercise Tolerance